Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01199562 · ClinicalTrials.gov registry record

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

A clinical trial of Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), sponsored by City of Hope Medical Center.

Active
Registry status
153
Enrollment target
1
Study location

NCT01199562: Active study of Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), sponsored by City of Hope Medical Center.

NCT01199562 is a study of Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 153 participants, above the 113-participant average among 29 other Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trials with a reported enrollment target (35% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01199562, a study of Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
153 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously treated with donor stem cell transplant.

Primary Outcome

Subjects will not be considered treated with anti-CMV agents unless at least 4 consecutive days of therapy are completed.

Interventions

  • OTHER laboratory biomarker analysis
  • PROCEDURE infection prophylaxis and management
  • OTHER flow cytometry
  • GENETIC DNA analysis
  • GENETIC RNA analysis

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 153 participants
Start Date 2010-12
Est. Completion 2026-12-01
City of Hope Medical Center

582 total trials

What the registry record for NCT01199562 still lists

NCT01199562 is an observational study that tracks outcomes without assigning an intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, above the 113-participant average among 29 other Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trials with a reported enrollment target (35% higher).

The record links to 10 conditions, with Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.

NCT01199562 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01199562 about?

NCT01199562 is a clinical study titled "Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant". RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously trea...

What is the current status of trial NCT01199562?

This trial is currently active not recruiting. The enrollment target is 153 participants. The study started on 2010-12. Estimated completion is 2026-12-01.

What conditions does trial NCT01199562 study?

This clinical trial studies the following conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With Del(5q).

What interventions are being tested in trial NCT01199562?

The interventions under investigation include: laboratory biomarker analysis (OTHER), infection prophylaxis and management (PROCEDURE), flow cytometry (OTHER), DNA analysis (GENETIC), RNA analysis (GENETIC).

Who is sponsoring clinical trial NCT01199562?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01199562 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01199562's enrollment target sits among peer trials

153 4th of 29 higher than 26 of 29 other Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05283265 · 153 participants · NA

    Neurophysiological Mechanisms of Language Comprehension

  • NCT05554393 · 153 participants · Phase 2

    Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • NCT05584501 · 153 participants · NA

    ETE Interventions in the Dental Setting

  • NCT05714839 · 153 participants · Phase 1

    A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01199562, the US trial registry maintained by the National Library of Medicine. NCT01199562 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.